[go: up one dir, main page]

WO2021207860A1 - Composition d'herbes et d'épices destinée à être utilisée en médecine - Google Patents

Composition d'herbes et d'épices destinée à être utilisée en médecine Download PDF

Info

Publication number
WO2021207860A1
WO2021207860A1 PCT/CH2020/050004 CH2020050004W WO2021207860A1 WO 2021207860 A1 WO2021207860 A1 WO 2021207860A1 CH 2020050004 W CH2020050004 W CH 2020050004W WO 2021207860 A1 WO2021207860 A1 WO 2021207860A1
Authority
WO
WIPO (PCT)
Prior art keywords
alcohol extract
composition
allium sativum
matricaria chamomilla
syzygium aromaticum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CH2020/050004
Other languages
English (en)
Inventor
René VENDEVILLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/CH2020/050004 priority Critical patent/WO2021207860A1/fr
Publication of WO2021207860A1 publication Critical patent/WO2021207860A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Definitions

  • composition of herbs and spices for use in medicine Composition of herbs and spices for use in medicine
  • the present invention relates to synergistic compositions that comprise a liquid alcohol extract of herbs and spices for use in therapy and ayurvedic remedy, particularly in the treatment of inflammation and cytokine storm.
  • Garlic is the species in the onion genus Allium, Allium sativum. It is native to Asia and has long been a common seasoning worldwide, with a history of thousand years of human consumption and use. Garlic contains diallyl disulfide, an anti-inflammatory compound that limits the effects of pro-inflammatory cytokines. Schafer G and Kaschula CH. Anticancer Agents Med Chem. 2014, 14(2):233-40.
  • Cloves are the flower buds of a tree in the family Myrtaceae, Syzygium aromaticum also known as Eugenia caryophyllata. Cloves are native to Indonesia and are commonly used as a spice. Cloves are used in traditional medicine as the essential oil to treat upset stomach, nausea, and inflammation of the mouth and throat. Han X and Parker TL. Pharm Biol. 2017, 55(1):1619-1622.
  • Chamomille is the species in the genus Matricaria, Matricaria chamomilla, commonly known as chamomile.
  • Chamomile is commonly used in herbal medicine, in particular as anti-inflammatory herb. Srivastava JK, Shankar E, Gupta S. Mol Med Rep. 2010, 3(6) :895-901.
  • Artichoke is the species in the genus Cynara, Cynara cardunculus, also known as French artichoke. Extracts of artichoke has been shown to have anti-inflammatory properties. Tang X, Wei R, Deng A, Lei T. Nutrients. 2017, 9(9).
  • the inflammation is the complex biological response triggered by infection, irritation, or injury of the body tissues to protect the host from systemic infection and help to restore tissue homeostasis.
  • the response consists of changes in blood flow, an increase in permeability of blood vessels, and the migration of immune cells from the circulation to the site of tissue damage.
  • a production of pro-inflammatory cytokines such as TNF-a, IL-lb, and IL-6 is causal to the induction of the inflammatory response.
  • cytokine storm excessive production of cytokine, known as "cytokine storm”
  • deregulated inflammation can result in injury of tissues. Cytokine storm have been shown is associated with the pathogenesis of multiple disease states ranging from viral infection to neurological disorders. TisoncikJR etal.
  • Nonsteroidal anti-inflammatory drugs such as aspirin, ibuprofen, and naproxen are the most common class of anti-inflammatory agents, available over the counter (OTC) in most countries.
  • OTC counter
  • the use of NSAIDs is associated with adverse effects. Gastrointestinal toxicity from NSAIDs includes dyspepsia, ulcers and bleeding.
  • Corticosteroids are another commonly used class for the treatment of inflammation; however, their use in patients with viral infections e.g. SARS of 2003, has been shown may increase risk of mortality.
  • compositions comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus.
  • a first aspect of the invention relates to an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus.
  • the invention relates to a process for the manufacture of an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus, which comprises a step of extracting a mixture of 1 to 8 parts by weight of Allium sativum, 1 to 2 parts by weight of Syzygium aromaticum, 1 to 2 parts by weight of Matricaria chamomilla, and 1 to 2 parts by weight of Cynara cardunculus with 130 to 170 parts by weight of alcohol.
  • the invention relates to a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use as an ayurvedic remedy.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in therapy.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in the treatment of inflammation.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in the treatment of cytokine storm.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in the protection of vascular system.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in the protection of central nervous system.
  • compositions may be formulated as a concentrated solution, a drop, a beverage, and syrup.
  • compositions of the invention can be advantageously used for preventing, diminishing or eliminating symptoms of inflammation and cytokine storm.
  • the present invention relates to compositions that are safe and effective to prevent and treat inflammation caused by infection, irritation, or injury of the body tissues, in particular associated with excessive production of pro-inflammatory cytokines known as cytokine storm.
  • the compositions of the inventions are capable of maintaining healthy and enhancing functional outcome in humans.
  • a first aspect of the invention relates to an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus.
  • alcohol refers to ethyl alcohol.
  • alcohol extract refers to material that has been prepared in a process comprising a step of extracting a raw material with alcohol.
  • Allium sativum is the latin name of garlic, the species in the onion genus Allium.
  • chopped garlic cloves are used as a raw material in manufacture of the alcohol extract of the present invention.
  • Syzygium aromaticum is the latin name of cloves, the species in the family Myrtaceae, also known as Eugenia caryophyllata.
  • the flower buds of cloves are used as a raw material in manufacture of the alcohol extract of the present invention.
  • Matricaria chamomilla is the latin name of chamomille, also known as chamomile, the species in the genus Matricaria.
  • the dried chamomille flowers are used as a raw material in manufacture of the alcohol extract of the present invention.
  • Cynara cardunculus is the latin name of artichoke, also known as French artichoke, the species in the genus Cynara.
  • the artichoke leafs are used as a raw material in manufacture of the alcohol extract of the present invention.
  • the term "synergistically effective" in this context means that the effect of the alcoholic extract of four materials Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus is higher than the sum of the effects of extracts of individual materials Allium sativum, Syzygium aromaticum, Matricaria chamomilla, or Cynara cardunculus taken in the same amounts.
  • the inventors found that individuals, who consumed a composition of the invention, observed either no symptoms of inflammation or a significant reduction in at least one of the symptoms of inflammation. Without been bound to a theory, the inventors suggest that the effect of the composition of the invention could be associated with their discovery that the components of the extract work in synergy to suppress undesirable excessive production of pro-inflammatory cytokines and, thus, inhibit symptoms of inflammation.
  • the invention relates to a process for the manufacture of an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus, which comprises a step of extracting a mixture of 1 to 8 parts by weight of Allium sativum, 1 to 2 parts by weight of Syzygium aromaticum, 1 to 2 parts by weight of Matricaria chamomilla, and 1 to 2 parts by weight of Cynara cardunculus with 130 to 170 parts by weight of alcohol.
  • the alcoholic extract is prepared by extracting a mixture of 4 parts by weight of Allium sativum, 1 part by weight of Syzygium aromaticum, 1 part by weight of Matricaria chamomilla, and 1 part by weight of Cynara cardunculus with 150 parts by weight of alcohol and filtering the extracting mixture to obtain a clear liquid alcohol extract.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus.
  • the composition can contain from 0.01 to 99.99 per cent of the alcohol extract.
  • the composition can contain some other optional ingredients.
  • optional ingredients generally are used individually at levels from about 0.01% to about 99.99% by weight of the composition.
  • suitable optional ingredients include, but are not limited to, herbs and spices, carriers, minerals, carbohydrates, lipids, vitamins, co-factors, buffers, flavors and sweeteners, inorganic salts, cations and anions typically abandoned in natural drinking water, taste modifying and/or masking agents, carbon dioxide, amino acids, organic acids, antioxidants, preservatives, colorants, and other suitable ingredients.
  • Non-exclusive examples of optional herbs and spices to be used in the compositions of the invention are orange (Citrus X sinensis), cinnemon ( Cinnamomum cassia), horseraddish (Armoracia rusticana), lemon (Citrus limon), leek (Allium porrum), red rice (Oryza punctata), carrot ( Daucus carota), papaya ( Carica papaya), mint ( Mentha spicata), chili ( Capsicum annuum), black pepper ( Piper nigrum), and asparagus ( Asparagus officinalis). These herbs and spices contain a wide group of phenolic compounds effective in scavenging of reactive oxygen species and useful in for inhibition of free radical-mediated processes, frequently accompany the inflammation.
  • orange (Citrus X sinensis), cinnemon ( Cinnamomum cassia), horseraddish (Armoracia rusticana), lemon (Citrus limon), leek (Allium porrum), red rice (Oryza punctata), carrot ( Daucus carota), papaya ( Carica papaya), mint ( Mentha spicata), chili ( Capsicum annuum), black pepper ( Piper nigrum), and asparagus ( Asparagus officinalis) can be used in the production of composition of the present invention in form of alcoholic extracts.
  • an alcoholic extract of a herb selected from the group consisting of orange (Citrus X sinensis), cinnemon ( Cinnamomum cassia), horseraddish (Armoracia rusticana), lemon (Citrus limon), leek (Allium porrum), red rice (Oryza punctata), carrot ( Daucus carota), papaya ( Carica papaya), mint ( Mentha spicata), chili ( Capsicum annuum), black pepper ( Piper nigrum), and asparagus ( Asparagus officinalis), is prepared by extracting 1 to 8 parts by weight of a raw material of the herb with 130 to 170 parts by weight of alcohol.
  • Non-exclusive examples of ingredients which can serve as carriers include water; sugars, such as glucose, lactose, and sucrose; cellulose, and its derivatives; starches, such as corn starch and potato starch; malt; gelatin; excipients, such as cocoa butter; oils, such as olive oil, peanut oil, cottonseed oil, corn oil and soybean oil; polyols, such as glycerin, mannitol, sorbitol, and polyethylene glycol; agar; buffering agents; water; pH buffered solutions; and other non-toxic compatible substances employed in formulations. Sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • Non-exclusive examples of antioxidants are Vitamin E, ascorbic acid, carotenoids, aminoindoles, Vitamin A, flavonoids, polyphenols, herbal antioxidants, melatonin, lipoic acids, and mixtures thereof.
  • Non-exclusive examples of useful inorganic salts typically are sea salt, sodium carbonate, sodium bicarbonate, magnesium chloride, calcium chloride, and mixtures thereof.
  • Non-exclusive examples of suitable buffers are phosphate buffer, glycine buffer, citrate buffer, acetate buffer, carbonate buffer, and succinate buffer.
  • Non-exclusive examples of suitable flavors are synthetic flavor oils; plant extracts, flowers, leaves, fruits, vanilla, chocolate, mocha, coffee, apple, pear, peach, citrus such as lemon, orange, grape, lime, and grapefruit; flavoring aromatics and naturals oils such as cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leave oil, oil of nutmeg, oil of sage, oils of citrus fruits, oil of bitter almonds, and cassia oil; mango, strawberry, raspberry, cherry, plum, pineapple, and apricot, and combinations thereof.
  • Non-exclusive examples of suitable sweeteners are natural and synthetic sweeteners.
  • Non-exclusive examples of natural sweeteners are naturally occurring substances, sucrose, extracts from naturally occurring substances; extracts of the plant Stevia Rebaudiana Compositae Bertoni such as stevia, steviol, rebaudiosides A-F, and dulcosides A and B; extracts of Thladiantha grosvenorii such as mogroside V and related glycosides and triterpene glycosides; phyllodulcin and its derivatives; thaumatin and its derivatives; mogrosides such as mogroside IV, mogroside V, siamenoside, and mixtures thereof; genus Siraitia including S. grosvenorii, S.
  • siamensis S. silomaradjae, S. sikkimensis, S. Africana, S. borneesis, and S. taiwaniana; naturally-occurring glycosides; and active compounds of plant origin having sweetening properties, and mixtures thereof.
  • Non-exclusive examples of useful organic acids are acetic acid, malic acid, pyruvic acid, glutamic acid, citric acid, omega-3 unsaturated acids, linoleic acid, linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, aspartic acid, and mixtures thereof.
  • Non-exclusive examples of useful amino acids are Glycine, Arginine, L- Tryptophan, L-Lysine, Methionine, Threonine, and L-carnitine.
  • Non-exclusive examples of useful vitamins are thiamin, riboflavin, nicotinic acid, panthothenic acid, biotin, folic acid, pyridoxine, vitamin B12, lipoic acid, vitamin A, vitamin D, vitamin E, alpha, beta, and gamma carotenes; ascorbic acid, choline, carnitine, vitamin K, and mixtures thereof.
  • Non-exclusive examples of useful co-factors are thiamine pyrophosphates, Coenzyme A, coenzyme B12, flavin mononucleotide, flavin adenine dinucleotide, pyridoxal phosphate, biotin, tetrahydrofolic acid, and mixtures thereof.
  • the composition of the invention can be prepared by procedures well-known from the art. Such procedures include, but are not limited to, mixing the alcohol extract with other ingredients of the composition in conventional manner. Guidance for the preparation of compositions of the invention can be found in "Remington: The science and practice of pharmacy" 20th ed.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use as an ayurvedic remedy.
  • Ayurvedic remedy refers to a medicinal product derived mainly from plants to be used in combination with diet, exercise, and lifestyle based on a natural and holistic approach to physical and mental health in compliance with Ayurveda.
  • Ayurveda refers to the ancient Indian medical system known as Ayurveda.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in therapy.
  • the term "therapy” refers to any treatment which is designed to cure, alleviate, remove or lessen the symptoms of, or prevent or reduce the possibility of contracting any disorder or malfunction of the subject body.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in the treatment of inflammation.
  • treatment refers to the administration of a remedy to a patient for a disease or injury.
  • the composition can be administered by different routes.
  • routes include oral, buccal, sublingual, nasal, and rectal.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in the treatment of cytokine storm.
  • cytokine storm refers to an excessive or uncontrolled release of pro- inflammatory cytokines associated with infectious and noninfectious disease.
  • non-infectious diseases associated with cytokine storm include graft-versus-host disease, multiple sclerosis, pancreatitis, or multiple organ dysfunction syndrome.
  • infectious diseases associated with cytokine storm include viral diseases, especially influenza and coronavirus such as COVID-19.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in the protection of vascular system.
  • vascular system refers to the circulatory system that is made up of the vessels that carry blood and lymph through the body.
  • protection of vascular system refers to prevention of vascular system from damage caused by any means.
  • Nonexclusive examples of such means include stress, inflammation, and expression of molecules representing well-established risk factors for vascular diseases.
  • the invention relates to a composition
  • a composition comprising an alcohol extract of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus for use in the protection of central nervous system.
  • central nervous system refers to the part of the nervous system consisting primarily of the brain and spinal cord.
  • protection of central nervous system refers to prevention of central nervous system from damage or deterioration of functioning caused by any means.
  • Nonexclusive examples of such means include stress, neuroinflammation, and expression of molecules representing well-established risk factors for neurodegeneration.
  • the alcoholic extract of essential materials of the composition i.e. Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus
  • the effective amounts of the alcoholic extract may vary depending on the aim and/or method of use, and on the subject in need, or other circumstances. These embodiments are discussed below and exemplified by non limiting working examples. In some embodiments, the effective amounts of the alcoholic extract are from 0.01 to 100.00 g.
  • subject refers to a mammal, preferably human.
  • compositions of the present invention may be preferred to formulate as a concentrate, drops, capsule, elixirs, suspensions, syrups, gel, or any other type of consumer food product or medicinal product.
  • the alcohol extract is prepared by extracting raw materials of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus with alcohol, in amounts as indicated in Table 1, and filtering the extracting mixture to obtain clear liquid alcohol extract for the use in the manufacture of compositions of the present invention.
  • the alcohol extract is prepared by extracting raw materials of Allium sativum, Syzygium aromaticum, Matricaria chamomilla, and Cynara cardunculus with alcohol, in amounts as indicated in Table 2, filtering the extracting mixture to obtain clear liquid alcohol extract for the use in the manufacture of compositions of the present invention.
  • the alcohol extract is prepared by extracting raw materials of Allium sativum with alcohol, in amounts as indicated in Table 3, filtering the extracting mixture to obtain clear liquid alcohol extract for the use as one of the reference alcohol extracts in the study on synergy in effects (see Example 4).
  • the alcohol extract is prepared by extracting raw materials of Syzygium aromaticum with alcohol, in amounts as indicated in Table 4, filtering the extracting mixture to obtain clear liquid alcohol extract for the use as one of the reference alcohol extracts in the study on synergy in effects (see Example 4).
  • the alcohol extract is prepared by extracting raw materials of Matricaria chamomilla with alcohol, in amounts as indicated in Table 5, filtering the extracting mixture to obtain clear liquid alcohol extract for the use as one of the reference alcohol extracts in the study on synergy in effects (see Example 4).
  • the alcohol extract is prepared by extracting raw materials of Cynara cardunculus with alcohol, in amounts as indicated in Table 6, filtering the extracting mixture to obtain clear liquid alcohol extract for the use as one of the reference alcohol extracts in the study on synergy in effects (see Example 4).
  • Example 4 illustrates the synergistic efficacy of alcohol extract of the invention.
  • Table 7 shows that all tested extracts reduced IL-1 beta production in response to stimulation with LPS+IFN-y.
  • the anti-inflammatory effect of the alcohol extract of the invention consisting of four herbal components (group 2) (58.8% of reduction in IL-1 beta production) is higher than sum of effects of extracts of individual herbal components (groups 3, 4, 5, or 6) (48.4% of reduction in IL-1 beta production) taken in the same amounts as in the extract of the invention (group 2).
  • the alcohol extract of the invention is synergistically effective in the treating cytokine storm and inflammation over extracts of individual herbs and spices.
  • composition for use as an ayurvedic remedy demonstrates the composition for use as an ayurvedic remedy.
  • the ingredients are mixed in the conventional manner in amounts as indicated in Table 8 to prepare the composition for use as an ayurvedic remedy.
  • the composition is administered orally in therapeutically effective amounts of 5 ml to a subject in need thereof, daily, in combination with diet, exercise, and lifestyle based on a natural and holistic approach to physical and mental health in compliance with Ayurveda.
  • the ingredients are mixed in the conventional manner in amounts as indicated in Table 9 to prepare the composition for use in therapy.
  • the composition is administered orally in therapeutically effective amounts of 5 ml to a subject in need thereof, daily, to maintain the subject healthy and enhancing functional outcome.
  • Example 7
  • the ingredients are mixed in the conventional manner in amounts as indicated in Table 10 to prepare the composition for use in the treatment of inflammation and cytokine storm.
  • the composition is administered orally in therapeutically effective amounts of 5 ml to a subject in need thereof, daily, to prevent or treat inflammation and cytokine storm and maintain the subject healthy.
  • This example demonstrates the effect of the extract of the present invention on symptoms of inflammation and cytokine storm in animal model of stress-induced neuroinflammation.
  • mice 10-12-week-old, were assigned to one of three experimental groups: (1) control (non-stressed) non-treated mice, (2) stressed non-treated mice, and (3) stressed mice treated with 150 mI the alcohol extract of the present invention (Example 2, table 2), each comprising in six to eight animals.
  • Mice were subjected to a three-week ultrasound of unpredictably alternating frequencies 24/7(see below), while receiving daily respective treatments. Twenty-four hours after, their behavior was subsequently investigated in the open field to estimate functional outcome.
  • mice were killed 16h after the end of the test and brains were used for quantitative reverse transcriptase PCR (qRTPCR) of IL-lbeta, IL-6, and TNF-alpha assays to assess the effect of the treatment on neuroinflammation and cytokine storm in mice.
  • Results are presented in as mean ⁇ SEM of relative expression of pro-inflammatory cytokines in hippocampus (table 11) and total number of rears in the open field test (table 12).
  • Table 11 Relative expression of pro-inflammatory cytokines (cytokine storm).
  • Table 11 shows that three weeks of stress resulted in significant increase in levels of pro-inflammatory cytokines TNF-alpha, IL-l-beta, and IL-6 in hippocampus of mice (group 2) as compared to non-stressed non-treated control mice (group 1; p ⁇ 0.05), indicating the onset of cytokine storm and neuroinflammation.
  • Treatment of chronically stressed mice with the extract of the present invention (group 3) resulted in significant inhibition of cytokine production as compared to stressed non-treated mice (group 2; p ⁇ 0.05).
  • Table 12 shows that three weeks of stress resulted in significant impairment of exploratory behaviour associated with neuroinflammation.
  • the extract of the present invention protected nervous system against chronic stress and neuroinflammation and maintains healthy brain function.
  • LPS E. coli 0111:B4, Sigma-Aldrich
  • the animals received a final dose of the extract or vehicle immediately prior to the i.p. LPS.
  • WBC white blood cells
  • lymphocytes were measured in the blood and gene expression of markers of inflammation in the lung. Results are presented as mean ⁇ SEM of number of WBC and lymphocytes (table 13) and relative expression of markers of inflammation in the lung (table 14). [0102] Table 13. Absolute number of WBC and lymphocytes.
  • Table 13 shows that the extract of the present invention protected against the LPS-induced acute lymphopenia.
  • Table 14 Relative expression of markers of inflammation in the lung.
  • Table 14 shows that the extract of the present invention markedly reduced expression of serum amyloid A-2 (SAA-2) protein, C-reactive protein (CRP), and C-X-C motif chemokine 10 (CXCL10) also known as Interferon gamma-induced protein 10 (IP- 10), the well-known markers of inflammation, in the lung.
  • SAA-2 serum amyloid A-2
  • CRP C-reactive protein
  • CXCL10 C-X-C motif chemokine 10
  • IP- 10 Interferon gamma-induced protein 10

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne des extraits alcooliques d'Allium sativum, de Syzygium aromaticum, de Matricaria chamomilla, et de Cynara carunculous et leur procédé de fabrication, ainsi que des compositions de ceux-ci à utiliser en tant que remède ayurvédique et en thérapie, notamment dans le traitement d'une inflammation et d'une tempête de cytokines, et dans la protection du système vasculaire et du système nerveux central.
PCT/CH2020/050004 2020-04-13 2020-04-13 Composition d'herbes et d'épices destinée à être utilisée en médecine Ceased WO2021207860A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CH2020/050004 WO2021207860A1 (fr) 2020-04-13 2020-04-13 Composition d'herbes et d'épices destinée à être utilisée en médecine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CH2020/050004 WO2021207860A1 (fr) 2020-04-13 2020-04-13 Composition d'herbes et d'épices destinée à être utilisée en médecine

Publications (1)

Publication Number Publication Date
WO2021207860A1 true WO2021207860A1 (fr) 2021-10-21

Family

ID=71527532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2020/050004 Ceased WO2021207860A1 (fr) 2020-04-13 2020-04-13 Composition d'herbes et d'épices destinée à être utilisée en médecine

Country Status (1)

Country Link
WO (1) WO2021207860A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004301A1 (en) * 2003-03-21 2009-01-01 Elizabeth Mazzio Method of treating dyshidrosis(pompholyx) and related dry skin disorders
WO2018189672A1 (fr) * 2017-04-12 2018-10-18 Herbal E Antioxidant Derivatives S.R.L. Ed In Forma Abbreviata H&Ad S.R.L. Extraits de cynara cardunculus et de citrus aurantium bergamia, leurs combinaisons et formulations les contenant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004301A1 (en) * 2003-03-21 2009-01-01 Elizabeth Mazzio Method of treating dyshidrosis(pompholyx) and related dry skin disorders
WO2018189672A1 (fr) * 2017-04-12 2018-10-18 Herbal E Antioxidant Derivatives S.R.L. Ed In Forma Abbreviata H&Ad S.R.L. Extraits de cynara cardunculus et de citrus aurantium bergamia, leurs combinaisons et formulations les contenant

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"Encyclopaedia of Pharmaceutical Technology", 1988, MARCEL DEKKER, INC.
"Remington: The science and practice of pharmacy", 2000, MACK PUBLISHING
GEORGIA SCHÄFER ET AL: "The Immunomodulation and Anti-Inflammatory Effects of Garlic Organosulfur Compounds in Cancer Chemoprevention", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol. 14, no. 2, 31 January 2014 (2014-01-31), NL, pages 233 - 240, XP055756123, ISSN: 1871-5206, DOI: 10.2174/18715206113136660370 *
GUPTA: "Chamomile: A herbal medicine of the past with a bright future (Review)", MOLECULAR MEDICINE REPORTS, vol. 3, no. 6, 28 September 2010 (2010-09-28), GR, XP055736540, ISSN: 1791-2997, DOI: 10.3892/mmr.2010.377 *
HAN XPARKER TL., PHARM BIOL., vol. 55, no. 1, 2017, pages 1619 - 1622
HUI DSCZUMLA A., INFECT DIS CLIN NORTH AM., vol. 33, no. 4, 2019, pages 869 - 889
LAINE L., CARDIOVASC PHARMACOL., vol. 47, no. 1, 2006, pages S60 - 6
SCHAFER GKASCHULA CH, ANTICANCER AGENTS MED CHEM., vol. 14, no. 2, 2014, pages 233 - 40
SHRIDAS P ET AL., CURR OPIN LIPIDOL., vol. 30, no. 4, 2019, pages 320 - 325
SRIVASTAVA JKSHANKAR EGUPTA S., MOL MED REP., vol. 3, no. 6, 2010, pages 895 - 901
TANG XWEI RDENG ALEI T., NUTRIENTS, vol. 9, no. 9, 2017
THOMPSON JC ET AL., J LIPID RES., vol. 56, no. 2, 2015, pages 286 - 93
TISONCIK JR ET AL., MICROBIOL MOL BIOL REV., vol. 76, no. l, 2012, pages 16 - 32
XUESHENG HAN ET AL: "Anti-inflammatory activity of clove ( Eugenia caryophyllata ) essential oil in human dermal fibroblasts", PHARMACEUTICAL BIOLOGY, vol. 55, no. 1, 1 January 2017 (2017-01-01), NL, pages 1619 - 1622, XP055756124, ISSN: 1388-0209, DOI: 10.1080/13880209.2017.1314513 *
ZHOU J ET AL., INFLAMM RES., vol. 69, no. 4, 2020, pages 331 - 345

Similar Documents

Publication Publication Date Title
Zovko Koncic et al. New insights into dietary supplements used in sport: active substances, pharmacological and side effects
Vlachojannis et al. A systematic review on the sambuci fructus effect and efficacy profiles
CN104223284B (zh) 一种功能饮料及其生产方法和用途
Gulati et al. Nutraceuticals in respiratory disorders
KR20060020923A (ko) 숙취해소 및 간기능 개선용 식품 조성물
ES2398371T3 (es) Composición que comprende los extractos de lindera obtusiloba para la prevención y el tratamiento de enfermedades cardiovasculares
ES2400580T3 (es) Una composición que comprende el extracto de hierbas combinadas para prevenir y tratar enfermedades hepáticas
CN102178885B (zh) 一种用于醒酒的药物组合物
KR101930277B1 (ko) 숙취 예방 및 개선용 조성물
KR101827326B1 (ko) 숙취해소용 한약재 조성물
KR101789424B1 (ko) 구기자를 포함하는 수면장애 개선용 한방조성물 및 그 제조방법
KR20130020095A (ko) 멀꿀 추출물을 포함하는 간 보호용 조성물
JP7199518B2 (ja) 補虚損用ヘルスケア製品組成物、その製造方法及び使用
Mahmood et al. Foeniculum vulgare, Solanum nigrum and Cichorium intybus: A Collectanea of Pharmacological and Clinical uses
Yampolsky et al. Sea buckthorn (lat. Hippophaë)
KR102564887B1 (ko) 호흡기질환 예방 및 개선용 조성물
JP2020514285A (ja) 龍眼肉抽出物を含有する二日酔い予防または解消用組成物
JP2018506524A (ja) バーンアウト症候群の予防、改善、または治療用組成物
WO2021207860A1 (fr) Composition d'herbes et d'épices destinée à être utilisée en médecine
Ibadullayeva Traditional folk medicine of Azerbaijanis
KR20040052930A (ko) 숙취해소용 조성물 및 이를 유효성분으로 함유하는숙취해소제
US12491167B2 (en) Plant based supplement compositions
CN108714164A (zh) 连翘叶红茶提取物的用途
KR101248378B1 (ko) 관절염 치료 및 예방용 약학조성물
JP4838301B2 (ja) 宿酔の予防または治療用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20737334

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22.05.2023)

122 Ep: pct application non-entry in european phase

Ref document number: 20737334

Country of ref document: EP

Kind code of ref document: A1